Furie, R., Bomba, D., Dall’era, M., Prieto, M., Anderl, J., Wang, J., … Goel, N. (2019). FRI0196 TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS WITH THE IMMUNOPROTEASOME INHIBITOR KZR-616: RESULTS FROM THE FIRST 2 COHORTS OF AN OPEN-LABEL PHASE 1B DOSE ESCALATION TRIAL. In Annals of the Rheumatic Diseases (Vol. 78, pp. 776–777). Elsevier BV. https://doi.org/10.1136/annrheumdis-2019-eular.1955

Furie, Richard, Darrin Bomba, Maria Dall’era, Massiel Prieto, Janet Anderl, Jinhai Wang, Christopher Kirk, and Niti Goel. “FRI0196 TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS WITH THE IMMUNOPROTEASOME INHIBITOR KZR-616: RESULTS FROM THE FIRST 2 COHORTS OF AN OPEN-LABEL PHASE 1B DOSE ESCALATION TRIAL.” In Annals of the Rheumatic Diseases, 78:776–77. Elsevier BV, 2019. https://doi.org/10.1136/annrheumdis-2019-eular.1955.

Furie R, Bomba D, Dall’era M, Prieto M, Anderl J, Wang J, et al. FRI0196 TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS WITH THE IMMUNOPROTEASOME INHIBITOR KZR-616: RESULTS FROM THE FIRST 2 COHORTS OF AN OPEN-LABEL PHASE 1B DOSE ESCALATION TRIAL. In: Annals of the Rheumatic Diseases. Elsevier BV; 2019. p. 776–7.

Furie, Richard, et al. “FRI0196 TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS WITH THE IMMUNOPROTEASOME INHIBITOR KZR-616: RESULTS FROM THE FIRST 2 COHORTS OF AN OPEN-LABEL PHASE 1B DOSE ESCALATION TRIAL.” Annals of the Rheumatic Diseases, vol. 78, Elsevier BV, 2019, pp. 776–77. Crossref, doi:10.1136/annrheumdis-2019-eular.1955.

Furie R, Bomba D, Dall’era M, Prieto M, Anderl J, Wang J, Kirk C, Goel N. FRI0196 TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS WITH THE IMMUNOPROTEASOME INHIBITOR KZR-616: RESULTS FROM THE FIRST 2 COHORTS OF AN OPEN-LABEL PHASE 1B DOSE ESCALATION TRIAL. Annals of the Rheumatic Diseases. Elsevier BV; 2019. p. 776–777.